[Monitoring sheet covering long-term chemotherapy to predict individual adverse reaction patterns for patients with gynecologic chemotherapy].
Monitoring the adverse reaction patterns specific to individual patients is important to avoid subsequent reactions. Gynecologic cancer chemotherapy is often implemented repeatedly with an altered protocol during prolonged terms. The purpose of this study was to develop and assess the efficacy of a worksheet that pharmacists can use to analyze adverse reaction patterns in individual patients with gynecologic chemotherapy. The worksheet which we developed consisted of multiple sections. One section is for necessary drug information for the proper use of antineoplastic agents. Another section is for the following items recorded by the pharmacists: a) patients' basic information such as stage of disease and protocol, b) state of implementation and break of chemotherapy and supportive therapy on calendar, and c) laboratory data and symptoms. We arranged the last item below the calendar and enabled pharmacists to easily assess individual adverse reactions coupled with the treatment course. Reviews of the developed worksheet indicated that the worksheet led to the convenient detection of individual adverse reaction patterns and effective prevention of additional adverse reactions. This monitoring sheet covering long-term chemotherapy which was designed to predict individual adverse reaction patterns will improve the individualization and safety of gynecologic chemotherapy.
Doi
Chiaki
C
Department of Pharmacy, Kagawa University Hospital, Japan.
Iihara
Naomi
N
Kawazoe
Hitoshi
H
Fukuoka
Noriyasu
N
Houchi
Hitoshi
H
Kurosaki
Yuji
Y
Morita
Shushi
S
D016907:Adverse Drug Reaction Reporting Systems; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D004334:Drug Administration Schedule; D004346:Drug Information Services; D016903:Drug Monitoring / Q000379:methods*; D005260:Female; D005544:Forecasting; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D005791:Patient Care; D010593:Pharmaceutical Services; D013997:Time Factors
D000970:Antineoplastic Agents